Goldman Sachs raised the firm’s price target on SpringWorks Therapeutics to $59 from $54 and keeps a Buy rating on the shares after its Q4 results. The company’s results are indicative of a strong start for the Ogsiveo launch, especially given the drug was only available for one-third of the quarter, the analyst tells investors in a research note. SpringWorks also received investigational new drug clearance to study TEAD1 inhibitor SW-682 in patients with hippo pathway mutations and noted plans to initiate a Phase 1a trial in the first half of 2024, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SWTX:
- SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
- SpringWorks Therapeutics price target raised to $70 from $60 at Wedbush
- SpringWorks Therapeutics to Present at Upcoming Investor Conferences
- SpringWorks Therapeutics CDO Resigns, Assumes Advisory Role
- SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
